| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
|
N Engl J Med
|
2004
|
30.26
|
|
2
|
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
20.89
|
|
3
|
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
Lancet Oncol
|
2010
|
13.25
|
|
4
|
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
|
Lancet
|
2012
|
12.00
|
|
5
|
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
|
N Engl J Med
|
2013
|
11.93
|
|
6
|
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
11.73
|
|
7
|
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
|
J Clin Oncol
|
2007
|
11.04
|
|
8
|
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
J Clin Oncol
|
2010
|
10.17
|
|
9
|
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
|
Nature
|
2012
|
8.77
|
|
10
|
Detection of circulating tumor DNA in early- and late-stage human malignancies.
|
Sci Transl Med
|
2014
|
8.36
|
|
11
|
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
JAMA
|
2010
|
8.21
|
|
12
|
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
|
Lancet Oncol
|
2005
|
7.43
|
|
13
|
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
|
Cancer Res
|
2007
|
5.54
|
|
14
|
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
|
J Clin Oncol
|
2010
|
5.10
|
|
15
|
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
|
Cancer Res
|
2009
|
4.82
|
|
16
|
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
|
Eur J Cancer
|
2012
|
4.29
|
|
17
|
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
|
Cancer Discov
|
2011
|
3.86
|
|
18
|
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
|
J Natl Cancer Inst
|
2002
|
3.54
|
|
19
|
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
|
J Clin Oncol
|
2012
|
3.04
|
|
20
|
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
|
Cancer Discov
|
2013
|
2.87
|
|
21
|
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
|
J Clin Oncol
|
2008
|
2.57
|
|
22
|
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
|
J Clin Oncol
|
2008
|
2.44
|
|
23
|
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
|
Lancet Oncol
|
2008
|
2.40
|
|
24
|
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
|
Eur Urol
|
2006
|
2.38
|
|
25
|
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
|
J Clin Oncol
|
2007
|
2.19
|
|
26
|
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
|
PLoS One
|
2009
|
2.18
|
|
27
|
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
|
Oncologist
|
2005
|
2.17
|
|
28
|
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
|
J Thorac Oncol
|
2012
|
2.15
|
|
29
|
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
|
J Clin Oncol
|
2005
|
2.10
|
|
30
|
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
Clin Cancer Res
|
2013
|
2.03
|
|
31
|
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
|
J Clin Oncol
|
2012
|
1.97
|
|
32
|
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
|
Pediatr Blood Cancer
|
2009
|
1.94
|
|
33
|
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
|
Sci Transl Med
|
2014
|
1.79
|
|
34
|
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
|
J Clin Oncol
|
2008
|
1.61
|
|
35
|
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
|
Cytotherapy
|
2011
|
1.54
|
|
36
|
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
|
Haematologica
|
2006
|
1.53
|
|
37
|
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
|
Anticancer Drugs
|
2009
|
1.42
|
|
38
|
Targeted therapies: how personal should we go?
|
Nat Rev Clin Oncol
|
2011
|
1.31
|
|
39
|
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
|
Cancer
|
2009
|
1.31
|
|
40
|
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
|
Int J Cancer
|
2013
|
1.26
|
|
41
|
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
|
Nat Med
|
2015
|
1.12
|
|
42
|
Regorafenib for metastatic colorectal cancer.
|
Lancet
|
2013
|
1.09
|
|
43
|
EGFR FISH in colorectal cancer: what is the current reality?
|
Lancet Oncol
|
2008
|
1.04
|
|
44
|
Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
|
Anticancer Res
|
2005
|
1.03
|
|
45
|
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
|
Cancer
|
2002
|
0.97
|
|
46
|
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.
|
J Clin Pathol
|
2011
|
0.94
|
|
47
|
Survival of adults treated for medulloblastoma using paediatric protocols.
|
Eur J Cancer
|
2005
|
0.93
|
|
48
|
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
|
Clin Cancer Res
|
2013
|
0.91
|
|
49
|
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
|
J Natl Cancer Inst
|
2013
|
0.91
|
|
50
|
An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.
|
Target Oncol
|
2013
|
0.90
|
|
51
|
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.
|
PLoS One
|
2011
|
0.89
|
|
52
|
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
|
Lung Cancer
|
2008
|
0.87
|
|
53
|
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.
|
Cancer
|
2005
|
0.87
|
|
54
|
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
|
Target Oncol
|
2010
|
0.86
|
|
55
|
Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.
|
PLoS One
|
2013
|
0.85
|
|
56
|
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
|
Cancer
|
2013
|
0.82
|
|
57
|
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
|
J Cancer Res Clin Oncol
|
2014
|
0.81
|
|
58
|
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
|
Clin Colorectal Cancer
|
2012
|
0.80
|
|
59
|
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
|
BMC Cancer
|
2012
|
0.80
|
|
60
|
Regorafenib in metastatic colorectal cancer.
|
Expert Rev Anticancer Ther
|
2014
|
0.79
|
|
61
|
Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.
|
Curr Gene Ther
|
2005
|
0.79
|
|
62
|
Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling.
|
Int J Cancer
|
2004
|
0.79
|
|
63
|
Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia.
|
Cancer
|
2009
|
0.79
|
|
64
|
Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation.
|
Haematologica
|
2007
|
0.78
|
|
65
|
Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in Italy.
|
Anticancer Res
|
2007
|
0.77
|
|
66
|
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.77
|
|
67
|
Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion.
|
Anticancer Res
|
2007
|
0.76
|
|
68
|
Absence of c-Kit and members of the epidermal growth factor receptor family in refractory germ cell cancer.
|
Cancer
|
2003
|
0.75
|
|
69
|
Iron supplement in cancer patients receiving erythropoietin.
|
J Clin Oncol
|
2004
|
0.75
|
|
70
|
Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy.
|
Anticancer Res
|
2009
|
0.75
|
|
71
|
Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.
|
Anticancer Res
|
2008
|
0.75
|
|
72
|
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research.
|
Future Oncol
|
2014
|
0.75
|
|
73
|
Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
|
Future Oncol
|
2006
|
0.75
|
|
74
|
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
|
Curr Opin Mol Ther
|
2010
|
0.75
|
|
75
|
Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
|
Chemotherapy
|
2008
|
0.75
|